Print this Article
RSSBusiness Wire
Gary Shangold, CEO of NovaDel Pharma, Inc. (AMEX: NVD), was interviewed by television reporters across the country yesterday concerning various methods of delivering prescription medication. The Company's approach is a fast acting lingual spray that could potentially deliver well-known and widely used drugs more conveniently and rapidly than existing methods.
A number of television stations interviewed Dr. Shangold, including KFTY-TV, San Francisco, and KJRH-TV, the NBC affiliate in Tulsa.
During the interviews, Dr. Shangold discussed how a lingual spray offers a valuable alternative to pills and other routes of delivery in terms of speed of onset, ease of use, and possibly even some side effects.
Anyone interested in receiving a CD of aired interviews may submit a request to cmazurek@investorrelationsgroup.com or sschroeder@investorrelationsgroup.com.
About NovaDel Pharma, Inc.
NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the development of novel drug delivery systems for prescription and over-the-counter drugs. The Company's proprietary lingual spray technology delivery system offers the patient the potential for (i) fast onset of action; (ii) improved drug safety by reducing the required drug dosage and reducing side effects; (iii) improved patient convenience and compliance; and (iv) enhanced dosage reliability. The Company plans to develop such products independently and through collaborative arrangements with major pharmaceutical and biotech companies. To find out more about NovaDel Pharma Inc., visit our website at http://www.novadel.com.
Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein including, but not limited to, the successful completion of its pilot pharmacokinetic feasibility studies, the ability to develop products (independently and through collaborative arrangements), the ability to commercialize and obtain FDA and other regulatory approvals for products under development and the acceptance in the marketplace for lingual spray products. Further, the Company operates in industries where securities may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's most recent Annual Report and Registration Statements, filed with the Securities and Exchange Commission. In assessing forward-looking statements contained herein, if any, the reader is urged to carefully read all cautionary statements contained in such filings.
